Companies › Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Professional Services 📍 Cambridge, United States 👥 1001-5000 employees 💰 $4.2B raised 📅 Founded 2002 🏷 ALNY

Alnylam is a biopharmaceutical company that develops RNA interference therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals has no current AI or cloud hiring signals in our index. Revenue growth: +65% YoY (annual revenue: $2.1B) — classified as 🚀 Hyper-Growth per SEC 10-K filing. Publicly traded as ALNY. Source: https://cloud.awsexpansion.com — AI and cloud hiring intelligence index. Data as of 2026-07-20.

📊 Company Overview

Sector
Professional Services
Country
United States
Employees
1001-5000
Public · ALNY
Listed
Founded
2002
Cloud
Unknown
CDN
Fastly
Email
Mimecast

📈 Financial Signals (SEC 10-K)

Annual Revenue$2.1B
Revenue Growth (YoY)+65.2%
Growth Tier🚀 Hyper-Growth

Source: SEC EDGAR annual filings (10-K). Revenue growth calculated YoY from reported figures. Cloud vendors extracted from MD&A and risk factor sections. View on EDGAR →

📰 Recent News

Alnylam Stock And 2 US Health Care Names With Earnings In Focus

Alnylam Stock And 2 US Health Care Names With Earnings In Focus  simplywall.st

simplywall.st · 20 Jul 2026
Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD

Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD  Investing.com

Investing.com · 17 Jul 2026
Alnylam Pharmaceuticals (ALNY) Proxy filing Summary

Alnylam Pharmaceuticals (ALNY) Proxy filing Summary  Quartr

Quartr · 17 Jul 2026
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth  ChartMill

ChartMill · 17 Jul 2026
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns (NASDAQ:ALNY)

Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns (NASDAQ:ALNY)  Seeking Alpha

Seeking Alpha · 16 Jul 2026

Via Google News · Updated weekly

🎯 Outreach Strategy

Discovery questions based on Alnylam Pharmaceuticals’s signals — paste into your AI or CRM

📈
Revenue Growth

“Revenue grew +65% last year — what infrastructure decisions are you making to keep pace with that trajectory? Where does cloud become the constraint?”

☁️ Cloud Infrastructure

🔒 Subscribers only Cloud Provider

Uses Fastly CDN — origin host undetectable

WorkspaceMimecast
CDNFastly

Detected via DNS records and HTTP response headers as of 2026-07-20.

💰 Estimated Cloud Spend

$9M $22M / year across cloud providers

🛠 Tech Stack & Marketing

Ad Platforms🔒 Subscribers only
Analytics & CRM🔒 Subscribers only
CMS / PlatformDrupal
Frontend Stack🔒 Subscribers only

Detected from Alnylam Pharmaceuticals's public homepage as of 2026-07-20.

🔍 Compare with Similar Companies

Same sector (Professional Services), similar size

Data detected 2026-07-20 · Methodology · Suggest a correction